Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison
Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison
Simple item page
Full item details
- dc.contributor.author
- Cholette, François
- Mesa, Christine
- Harris, Angela
- Ellis, Hannah
- Cachero, Karla
- Lacap, Philip
- Galipeau, Yannick
- Langlois, Marc-André
- Gingras, Anne-Claude
- Yansouni, Cedric P.
- Papenburg, Jesse
- Cheng, Matthew P.
- Chakraborty, Pranesh
- Stein, Derek R.
- Van Caeseele, Paul
- Bartlett, Sofia
- Krajden, Mel
- Goldfarb, David
- McGeer, Allison
- Osiowy, Carla
- Hankins, Catherine
- Mazer, Bruce
- Drebot, Michael
- Kim, John
- COVID-19 Immunity Task Force (CITF) working group
- dc.date.accessioned
- 2024-11-18T20:31:27Z
- dc.date.available
- 2024-11-18T20:31:27Z
- dc.date.issued
- 2021-12-07
- dc.description.abstract - en
- The true severity of infection due to COVID-19 is under-represented because it is based on only those who are tested. Although nucleic acid amplifications tests (NAAT) are the gold standard for COVID-19 diagnostic testing, serological assays provide better population-level SARS-CoV-2 prevalence estimates. Implementing large sero-surveys present several logistical challenges within Canada due its unique geography including rural and remote communities. Dried blood spot (DBS) sampling is a practical solution but comparative performance data on SARS-CoV-2 serological tests using DBS is currently lacking. Here we present test performance data from a well-characterized SARS-CoV-2 DBS panel sent to laboratories across Canada representing 10 commercial and 2 in-house developed tests for SARS-CoV-2 antibodies. Three commercial assays identified all positive and negative DBS correctly corresponding to a sensitivity, specificity, positive predictive value, and negative predictive value of 100% (95% CI = 72.2, 100). Two in-house assays also performed equally well. In contrast, several commercial assays could not achieve a sensitivity greater than 40% or a negative predictive value greater than 60%. Our findings represent the foundation for future validation studies on DBS specimens that will play a central role in strengthening Canada’s public health policy in response to COVID-19.
- dc.description.sponsorship
- Marc-André Langlois (M.-A.L.) holds a Canada Research Chair in Molecular Virology and Intrinsic Immunity. This study was supported in part by a COVID-19 Rapid Response grant to M.-A.L. by the Canadian Institute of Health Research (CIHR; OV1-170355) and by a grant supplement by the COVID-19 Immunity Task Force (CITF).
- dc.identifier.doi
- https://doi.org/10.1371/journal.pone.0261003
- dc.identifier.issn
- 1932-6203
- dc.identifier.pubmedID
- 34874948
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/3165
- dc.language.iso
- en
- dc.publisher - en
- PLOS
- dc.rights - en
- Creative Commons Attribution 4.0 International (CC BY 4.0)
- dc.rights - fr
- Creative Commons Attribution 4.0 International (CC BY 4.0)
- dc.rights.uri - en
- https://creativecommons.org/licenses/by/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by/4.0/deed.fr
- dc.subject - en
- Health
- Coronavirus diseases
- dc.subject - fr
- Santé
- Maladie à coronavirus
- dc.subject.en - en
- Health
- Coronavirus diseases
- dc.subject.fr - fr
- Santé
- Maladie à coronavirus
- dc.title - en
- Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison
- dc.type - en
- Article
- dc.type - fr
- Article
- local.acceptedmanuscript.articlenum
- e0261003
- local.article.journalissue
- 12
- local.article.journaltitle - en
- PLoS ONE
- local.article.journalvolume
- 16
- local.pagination
- 1-19
- local.peerreview - en
- Yes
- local.peerreview - fr
- Oui
Download(s)
Original bundle
1 - 1 of 1
Name: cholette-dried-blood-spot-specimens-sars-cov-2-antibody-testing.pdf
Size: 2.51 MB
Format: PDF
Collection(s)